Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioLife Solutions, Inc. (NASDAQ: BLFS) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on BioLife’s activities as a developer and supplier of cell processing tools and services and bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets.
Through periodic reports such as the Form 10-K annual report and Form 10-Q quarterly reports, investors can review disclosures on BioLife’s Cell Processing, Cold Chain, and Thawing product areas, its focus on biopreservation media and related tools, and the financial impact of divestitures and strategic transactions. These filings also describe the company’s use of GAAP and non-GAAP metrics, its presentation of discontinued operations related to divested subsidiaries, and other elements of its financial reporting framework.
Current reports on Form 8-K highlight specific material events, including quarterly earnings announcements, investor presentations, and the sale of its evo cold chain logistics subsidiary. Proxy materials such as the definitive proxy statement (DEF 14A) provide insight into corporate governance, board composition, executive compensation proposals, and matters submitted to stockholder votes at the annual meeting.
On Stock Titan, each new BioLife filing is captured from EDGAR and paired with AI-powered summaries that explain the key points in clear language. Users can quickly scan annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K) to understand changes in BioLife’s cell processing business, portfolio evolution, and governance decisions. The filings page also surfaces information relevant to topics such as equity awards and compensation policies discussed in proxy statements, helping investors interpret the regulatory record behind the BLFS stock.
BioLife Solutions (BLFS) reported an insider transaction by its President & CEO and Director. On October 22, 2025, the reporting person sold 37,795 shares of common stock at $27.3 per share under a Rule 10b5-1(c) trading plan. Following the sale, the reporting person beneficially owns 489,998 shares, held directly.
The filing notes the 10b5-1 plan was effective October 19, 2023 and was adopted to satisfy tax withholding obligations related to the vesting of restricted stock.
BioLife Solutions (BLFS) filed a Form 4 indicating CTO Sean Werner sold 275 shares of common stock at $27.82 on October 20, 2025. The filing states the trade was executed under a Rule 10b5-1(c) plan adopted effective 07-17-2024 to satisfy tax withholding related to restricted stock vesting. Following the transaction, Werner beneficially owned 26,037 shares, held directly.
BioLife Solutions (BLFS) director Joydeep Goswami reported an open-market sale of 1,334 shares of common stock on 10/16/2025. The transaction was executed at a weighted average price with trade prices ranging from $28.99 to $29.00.
Following the sale, the reporting person beneficially owns 46,652 shares directly. The filing states the trades were made under a Rule 10b5-1(c) trading plan adopted effective 12/13/2024.
BioLife Solutions (BLFS): Casdin Partners Master Fund reported an open‑market sale of 750,000 shares of common stock on 10/15/2025 at a weighted average price of $28.5471, executed in multiple trades within the $28.50–$28.8354 range. After the transactions, 5,957,165 shares were beneficially owned indirectly. The shares are held directly by the Master Fund and may be deemed to be indirectly beneficially owned by Casdin Capital, Casdin Partners GP, and Eli Casdin.
BioLife Solutions (BLFS) reported an insider transaction by its Chief Financial Officer. On 10/09/2025, the CFO executed a sale of 833 shares of common stock at a price of $27.36 per share. Following this transaction, the officer beneficially owns 183,353 shares, held directly.
The filing notes the sale was made pursuant to a Rule 10b5-1(c) trading plan, effective 01/03/2023, to satisfy tax withholding obligations arising from the vesting of restricted stock. This indicates a pre-established, automated plan tied to equity award taxation rather than a discretionary open‑market trade.
BioLife Solutions (BLFS) reported an insider transaction by its Chief Marketing Officer. On October 9, 2025, the officer sold 289 shares of common stock at $27.36 per share. Following the sale, the officer beneficially owned 133,617 shares, held directly. The filing notes the sale was made under a Rule 10b5-1(c) trading plan effective January 3, 2023, established to satisfy tax withholding obligations related to the vesting of restricted stock.
BioLife Solutions (BLFS) insider transaction: EVP & Chief Scientific Officer Aby J. Mathew reported selling 509 shares of common stock at $27.36 on October 9, 2025. The filing states the sale was made under a Rule 10b5-1(c) trading plan effective January 3, 2023, to cover tax withholding tied to restricted stock vesting. After the transaction, he beneficially owns 350,912 shares, held directly. The report was filed by one reporting person.
BioLife Solutions (BLFS) reported an insider transaction by its Chief Human Resources Officer, Sarah Aebersold. On 10/09/2025, she sold 188 shares of common stock at $27.36 per share and now beneficially owns 77,169 shares, held directly. The filing states the sale was executed under a Rule 10b5-1(c) trading plan, effective 01/03/2023, to satisfy tax withholding obligations tied to the vesting of restricted stock.
BioLife Solutions (BLFS) reported an insider transaction by its Chief Quality and Operations officer. On 10/09/2025, the reporting person sold 419 shares of common stock at $27.36 per share in a transaction coded “S.” The filing states this sale was made under a Rule 10b5-1(c) trading plan adopted effective 01-03-2023 to satisfy tax withholding obligations upon the vesting of restricted stock.
Following the sale, the reporting person beneficially owned 193,253 shares, held directly.
Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, reported the disposition of 714 shares of the company's common stock on 09/15/2025 at a price of $25.61 per share. The sale was effected under a Rule 10b5-1 trading plan adopted by the reporting person effective 12/11/2024. After the reported transaction, the reporting person beneficially owned 77,357 shares, held directly. The Form 4 was signed and filed on 09/17/2025, and the filing indicates it was submitted by one reporting person.
FAQ
What is the current stock price of Biolife Solutions (BLFS)?
What is the market cap of Biolife Solutions (BLFS)?
